by Emily Underwood BOSTON—Dude, check out these European perch. After swimming in water laced with a common antianxiety medication, the red-finned fish lose their inhibitions and gobble up prey at a much faster rate, according to a new study presented here today at the annual meeting of the American Association for the Advancement of Science (publisher of ScienceNOW). The animals act strangely even after being exposed to low concentrations of the medication found in rivers worldwide, suggesting that the drug and others like it could affect fish behavior and ecology even in small doses. Hundreds of different pharmaceuticals are able to slip past conventional wastewater treatment plants and into our waterways, says Jerker Fick, a toxicologist at Umeå University in Sweden and co-author of the new study. "They don't mysteriously go away after we excrete them." Scientists have known for a long time that many pharmaceuticals can persist in rivers and streams, and have behavioral effects on aquatic species in high doses, he says; however, determining whether more dilute concentrations have an effect is harder to establish. Several years ago, Fick and his colleagues discovered a common psychoactive medication called oxazepam in water samples from the River Fyris, which flows through Uppsala, the fourth largest city in Sweden. Oxazepam belongs to a class of drugs that make neurons less excitable and slower to transmit signals throughout the brain and is an "essential" treatment for panic attacks and other severe anxiety disorders, Fick says. Although the authors describe the concentration of the drug—0.58 micrograms per liter-1—as "unusually high," they also say it is comparable to levels found in rivers in other countries; however, there isn't enough research to know for sure how widespread the drug is. "This is not a particularly Swedish problem," says lead author Tomas Brodin of Umeå University. © 2010 American Association for the Advancement of Science

Keyword: Emotions; Aggression
Link ID: 17811 - Posted: 02.16.2013

Mo Costandi Prions are best known as the infectious agents that cause ‘mad cow’ disease and the human versions of it, such as variant Creutzfeldt–Jakob Disease. But the proteins also have at least one known useful function, in the cells that insulate nerves, and are suspected to have more. Now researchers have provided the first direct evidence that the proteins play an important role in neurons themselves. The team reports in the Journal of Neuroscience1 that prions are involved in developmental plasticity, the process by which the structure and function of neurons in the growing brain is shaped by experience. Prions come in two main forms: the normal version and the misfolded, infectious version. The normal version, known as cellular prion protein (or PrPC), is present in every cell of the body and helps to maintain the myelin sheath in the cells that protect the nerves2. But the molecule is abundant in neurons themselves, especially during development. Because it is tethered to the membrane, it is widely assumed to be involved in signalling between nerve cells, but little direct evidence has been found for this. Neurobiologist Enrico Cherubini of the International School for Advanced Studies in Trieste, Italy, and his colleagues therefore decided to look at the effects of electrical stimulation on slices of tissue from the hippocampus of healthy 3–7-day-old mice and of animals genetically engineered to lack the gene that encodes the prion protein. They used electrodes to stimulate individual cells at the same time as the networks of young neurons showed bursts of spontaneous electrical activity, or to simultaneously stimulate pairs of cells that are connected to each other. © 2013 Nature Publishing Group

Keyword: Prions; Aggression
Link ID: 17809 - Posted: 02.16.2013

By PAM BELLUCK A type of brain stimulation caused by a mild electric current that appears to have minimal negative side effects is showing promise as a potential treatment for major depression, according to several studies. The experimental therapy, known as transcranial direct current stimulation, or tDCS, involves a low-level charge about one-400th of that used in electroshock treatment. Unlike electroshock (also called electroconvulsive therapy or ECT), which is administered for a few seconds to patients under anesthesia, tDCS is given for 20 to 30 minutes continuously while patients are conscious. While doctors do not see it replacing electroshock, considered the most effective approach for major depression that has been treatment-resistant and requires urgent attention, tDCS does not appear to cause memory loss as electroshock can. Because it is inexpensive and easily administered, scientists say it might become an alternative or additional treatment for people whose depression is not completely helped by medication. “I think tDCS could be tried before ECT,” said Dr. Andre R. Brunoni, a psychiatrist at the University of São Paulo in Brazil and an author of a study published last week in The Journal of the American Medical Association-Psychiatry. Or, he said, it could be used “for avoiding drug treatment in patients that cannot use drugs.” Researchers said Dr. Brunoni’s study is the largest to date of about half a dozen studies in recent years. It is the first comparing tDCS with another treatment — in this case, sertraline, or Zoloft. The study, involving 120 patients, found that tDCS appeared to work about as well as a low dose of Zoloft, and that combined with Zoloft, it worked better than the drug or the stimulation alone. Zoloft and tDCS were equally safe. A few patients became manic, and some developed redness where electrodes were applied. Copyright 2013 The New York Times Company

Keyword: Depression
Link ID: 17789 - Posted: 02.12.2013

By Laura Sanders Psychiatry seemed poised on the edge of a breakthrough. In early 2011, after decades of no radically new drugs, a fundamentally different schizophrenia treatment promised relief from the psychotic hallucinations and delusions plaguing people with the disease. The new compound, devised by chemists at Eli Lilly and Co., hit a target in the brain that older medicines had ignored. All signs pointed to success. In mice, a similar molecule could block the schizophrenia-like effects of PCP. In people the new drug, LY2140023, appeared to curb psychotic behavior with few side effects, small pilot studies showed. In March 2011, Lilly began enrolling 1,100 people in a definitive Phase III clinical trial, the final test designed to show conclusively that the new compound worked. A year and a half later, the drug was dead. After years of work and millions of dollars of investment, the failure was crushing. People with schizophrenia were no better on the new drug than similar people taking a placebo, early results indicated. “I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness,” Jan Lundberg, president of Lilly Research Laboratories, said in a press release. Although the results were devastating, many in the field weren’t surprised. For new drugs designed to treat complex brain disorders such as schizophrenia, depression and anxiety, the odds of success are exceedingly slim. Given the current state of affairs in the drug discovery world, some would argue those odds are close to zero. Not a single drug designed to treat a psychiatric illness in a novel way has reached patients in more than 30 years, argues psychiatrist Christian Fibiger of the University of British Columbia in Kelowna, who described the problem in a 2012 Schizophrenia Bulletin editorial. “For me, the data are in,” says Fibiger, who has developed drugs at several major pharmaceutical companies. “We’ve got to change. This isn’t working.” © Society for Science & the Public 2000 - 2013

Keyword: Schizophrenia; Aggression
Link ID: 17782 - Posted: 02.11.2013

By JAMES DAO Over the past decade, about half a million veterans have received diagnoses of post-traumatic stress disorder or traumatic brain injury. Thousands have received both. Yet underlying the growing numbers lies a disconcerting question: How many of those diagnoses are definitive? And how many more have been missed? A series of articles and videos chronicling the experiences of military veterans who have returned from Iraq and Afghanistan but continue to confront the medical and psychological scars of battle. No one can say. Though PTSD is hardly new, diagnoses still largely rely on self-reported symptoms. And while severe brain injuries are often clearly diagnosable, finding evidence of mild T.B.I.’s, particularly older ones, can be all but impossible. It means that for a soldier who, five years after duty in Iraq, still feels “not right,” with symptoms from headaches to sleeping problems to irritability, doctors can only guess at the cause. Maybe PTSD. Maybe T.B.I. Maybe both. Now, in one of the largest studies of its kind, a team of researchers based out of New York University’s medical school have begun a five-year study to find biological signals, known as biomarkers, that could provide reliable, objective evidence of those so-called invisible injuries of war. © 2013 The New York Times Company

Keyword: Stress; Aggression
Link ID: 17777 - Posted: 02.09.2013

By PAM BELLUCK People with mental illness are 70 percent more likely to smoke cigarettes than people without mental illness, two federal health agencies reported Tuesday. New data from the Centers for Disease Control and Prevention and the Substance Abuse and Mental Health Services Administration show that one of every three adults with mental illness smokes, compared with one in five adults without mental illness. Adults with mental illness smoke about a third of all the cigarettes in the United States, and they smoke more cigarettes per month and are significantly less likely to quit than people without mental illness, the report said. There are nearly 46 million adults with mental illness in the United States, about a fifth of the population. “Many people with mental illness are at greater risk of dying early from smoking than of dying from their mental health conditions,” said Dr. Thomas R. Frieden, director of the Centers for Disease Control, during a press briefing. The report is based on information from the National Survey on Drug Use and Health, which interviewed 138,000 adults in their homes from 2009 to 2011. People were asked 14 questions to assess psychological distress and disability, and were deemed to have mental illness if their responses indicated they had a mental, behavior or emotional disorder in the past 12 months. Those with substance abuse or developmental disorders were not considered people with mental illness. The report did not include patients in psychiatric hospitals or individuals serving in the military. © 2013 The New York Times Company

Keyword: Schizophrenia; Aggression
Link ID: 17769 - Posted: 02.06.2013

A telltale boost of activity at the back of the brain while processing emotional information predicted whether depressed patients would respond to an experimental rapid-acting antidepressant, a National Institutes of Health study has found. “We have discovered a potential neuroimaging biomarker that may eventually help to personalize treatment selection by revealing brain-based differences between patients,” explained Maura Furey, Ph.D., of NIH’s National Institute of Mental Health (NIMH). Furey, NIMH’s Carlos Zarate, M.D., and colleagues, reported on their functional magnetic resonance imaging (fMRI) study of a pre-treatment biomarker for the antidepressant response to scopolamine, Jan. 30, 2013, online in JAMA Psychiatry. Scopolamine, better known as a treatment for motion sickness, has been under study since Furey and colleagues discovered its fast-acting antidepressant properties in 2006. Unlike ketamine, scopolamine works through the brain’s acetylcholine chemical messenger system. The NIMH team’s research has demonstrated that by blocking receptors for acetylcholine on neurons, scopolamine can lift depression in many patients within a few days; conventional antidepressants typically take weeks to work. But not all patients respond, spurring interest in a predictive biomarker. The acetylcholine system plays a pivotal role in working memory, holding information in mind temporarily, but appears to act by influencing the processing of information rather than through memory. Imaging studies suggest that visual working memory performance can be enhanced by modulating acetylcholine-induced activity in the brain’s visual processing area, called the visual cortex, when processing information that is important to the task.

Keyword: Depression; Aggression
Link ID: 17754 - Posted: 02.05.2013

Some but not all antidepressant drugs known as SSRIs pose a very small but serious heart risk, say researchers. Citalopram and escitalopram, which fall into this drug group, can trigger a heart rhythm disturbance, a new study in the British Medical Journal shows. UK and US regulators have already warned doctors to be extra careful about which patients they prescribe these medicines to. And they have lowered the maximum recommended dose. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) says people with pre-existing heart conditions should have a heart trace before going on these drugs, to check for a rhythm disturbance known as long QT interval. Experts reassure that complications are very rare and that in most cases the benefits for the patient taking the drug will outweigh the risks. Long QT QT interval is measured with an electrocardiogram (ECG) and varies with the heart rate - it gets longer when the heart beats slower and is shorter when the heart beats faster. Some variation is normal, but if it gets too long it can upset the timing of heartbeat with potentially dire consequences - dizziness, faints and, rarely, sudden death. To assess how common a problem long QT linked to SSRI use might be, US researchers decided to look at the medical records of more than 38,00 patients from New England. BBC © 2013

Keyword: Depression
Link ID: 17736 - Posted: 01.30.2013

By Rachel Ehrenberg A rare peek into drug company documents reveals troubling differences between publicly available information and materials the company holds close to its chest. In comparing public and private descriptions of drug trials conducted by pharmaceutical giant Pfizer, researchers discovered discrepancies including changes in the number of study participants and inconsistent definitions of protocols and analyses. The researchers, led by Kay Dickersin, director of the Center for Clinical Trials at the Johns Hopkins Bloomberg School of Public Health, gained access to internal Pfizer reports after a lawsuit made them available. Dickersin and her colleagues compared the internal documents with 10 publications in peer-reviewed journals about randomized trials of Pfizer’s anti-epilepsy drug gabapentin (brand name Neurontin) that tested its effectiveness for treating other disorders. The results, the researchers say, suggest that the published trials were biased and misleading, even though they read as if standard protocols were followed. That lack of transparency could mean that clinicians prescribe drugs based on incomplete or incorrect information. We could see all of the biases right in front of us all at once,” says Dickersin, who was an expert witness in the suit, which was brought by a health insurer against Pfizer. Pfizer lost the case in 2010, and a judge ruled it should pay $142 million in damages for violating federal racketeering laws in promoting Neurontin for treating migraines and bipolar disorder. Pfizer had in 2004 settled a case and paid $430 million in civil fines and criminal penalties for promoting Neurontin for unapproved use. © Society for Science & the Public 2000 - 2013

Keyword: Depression; Aggression
Link ID: 17735 - Posted: 01.30.2013

By Laura Sanders A massive effort to uncover genes involved in depression has largely failed. By combing through the DNA of 34,549 volunteers, an international team of 86 scientists hoped to uncover genetic influences that affect a person’s vulnerability to depression. But the analysis turned up nothing. The results are the latest in a string of large studies that have failed to pinpoint genetic culprits of depression. “I’m disappointed,” says study coauthor Henning Tiemeier of Erasmus Medical Center in Rotterdam, Netherlands. The negative finding, published online January 3 in Biological Psychiatry, “tells us that we have to be very modest,” he says. “Yet we think it’s doable to find some of the genes involved.” Depression seems to run in families, leading scientists to think that certain genes are partially behind the disorder. But so far, studies on people diagnosed with depression have failed to reveal these genes. Unlike earlier studies, the new study ignored depression diagnoses and instead focused solely on symptoms. Researchers combined the results of 17 studies that asked volunteers the same set of 20 questions about their emotional health at the time of the questionnaire. A person with many signs of depression scored high on the index (called CES-D), while a person with few signs scored low. The researchers hoped that capturing the continuum of symptoms — instead of a black-and-white depression diagnosis — would be a better way to ferret out the genes involved in depression. © Society for Science & the Public 2000 - 2013

Keyword: Depression; Aggression
Link ID: 17689 - Posted: 01.17.2013

By BENEDICT CAREY Susan Nolen-Hoeksema, a psychologist and writer whose work helped explain why women are twice as prone to depression as men and why such low moods can be so hard to shake, died on Jan. 2 in New Haven. She was 53. Her death followed heart surgery to correct a congenitally weak valve, said her husband, Richard Nolen-Hoeksema. Dr. Nolen-Hoeksema, a professor at Yale University, began studying depression in the 1980s, a time of great excitement in psychiatry and psychology. New drugs like Prozac were entering the market; novel talking therapies were proving effective, too, particularly cognitive behavior therapy, in which people learn to defuse upsetting thoughts by questioning their basis. Her studies, first in children and later in adults, exposed one of the most deceptively upsetting of these patterns: rumination, the natural instinct to dwell on the sources of problems rather than their possible solutions. Women were more prone to ruminate than men, the studies found, and in a landmark 1987 paper she argued that this difference accounted for the two-to-one ratio of depressed women to depressed men. She later linked rumination to a variety of mood and behavior problems, including anxiety, eating disorders and substance abuse. “The way I think she’d put it is that, when bad things happen, women brood — they’re cerebral, which can feed into the depression,” said Martin Seligman, a professor of psychology at the University of Pennsylvania, who oversaw her doctoral work. “Men are more inclined to act, to do something, plan, beat someone up, play basketball.” © 2013 The New York Times Company

Keyword: Depression; Aggression
Link ID: 17679 - Posted: 01.14.2013

By Susan Milius Imagining tiny creatures infiltrating human brains is creepy enough. But Marion Vittecoq knows she has been invaded. Her inner companions may be just hanging out — or they may be subtly changing her personality, manipulating her behavior or altering her risk of disease. Yet she doesn’t sound particularly upset. Not once in the course of a phone conversation and many e-mails did Vittecoq recommend wearing tinfoil hats or mention mind control by the CIA, the United Nations or little green men beaming rays from the moons of Uranus. She studies the ecology of parasites, especially the one-celled Toxoplasma gondii, which coincidentally is the creature that has invaded her brain. She doesn’t see it as an extra-ordinary intrusion. The parasite has wormed its way into an estimated one-third of people on the planet. In France, where Vittecoq works at both a CNRS national research lab in Montpellier and the Tour du Valat research center in Arles, nearly one-third to about one-half of adults carry hitchhiking T. gondii. CNRS research colleague Frédéric Thomas is also infected, and also doesn’t fret about it. In the United States, almost one in four residents over the age of 12 has the infection. In other parts of the world, rates are as high as 95 percent. An unlucky minority of these infected people become quite ill. Most, however, don’t even know that their muscles and brains carry the parasite. © Society for Science & the Public 2000 - 2013

Keyword: Depression; Aggression
Link ID: 17677 - Posted: 01.12.2013

Experts are questioning whether diet drinks could raise depression risk, after a large study has found a link. The US research in more than 250,000 people found depression was more common among frequent consumers of artificially sweetened beverages. The work, which will be presented at the American Academy of Neurology's annual meeting, did not look at the cause for this link. Drinking coffee was linked with a lower risk of depression. People who drank four cups a day were 10% less likely to be diagnosed with depression during the 10-year study period than those who drank no coffee. But those who drank four cans or glasses of diet fizzy drinks or artificially sweetened juice a day increased their risk of depression by about a third. Lead researcher Dr Honglei Chen, of the National Institutes of Health in North Carolina, said: "Our research suggests that cutting out or down on sweetened diet drinks or replacing them with unsweetened coffee may naturally help lower your depression risk." But he said more studies were needed to explore this. BBC © 2013

Keyword: Depression; Aggression
Link ID: 17676 - Posted: 01.12.2013

By Laura Sanders At birth, some infants are already saddled with brains that carry features of Alzheimer’s disease and schizophrenia. Newborns who carry certain versions of genes already show brain shrinkage reminiscent of that in adults with brain illnesses, a study of 272 newborn babies reveals. The new results, published online January 2 in Cerebral Cortex, illuminate what happens to the brain in the earliest stages of life, says neuroscientist Jay Giedd of the National Institute of Mental Health in Bethesda, Md., who was not involved in the study. “As we go through life, there are so many uncontrollable factors,” he says. “This is a way to see gene influences before the world steps in.” Until this study, scientists didn’t have a good idea of whether certain brain signatures — such as reduced volume in parts of the brain — were present from birth or whether they accumulated over a lifetime, says study coauthor Rebecca Knickmeyer of the University of North Carolina at Chapel Hill. To test this, Knickmeyer and her colleagues looked for the influence of 10 versions of seven genes on newborns’ brains. The researchers chose genes that affect how the brain grows and develops. These gene variants have also been linked to adult brain diseases, such as the ε4 version of the ApoE gene, which triples the risk of getting Alzheimer’s, and a version of the COMT gene, which has been implicated in schizophrenia. © Society for Science & the Public 2000 - 2013

Keyword: Alzheimers; Aggression
Link ID: 17669 - Posted: 01.12.2013

Elderly people with dementia should be prescribed antipsychotics carefully, say Ontario doctors who found men are at higher risk of hospitalization and death than women when the treatment begins. Researchers focused on new prescriptions of a class of drugs called atypical antipsychotics that are used to manage behaviour problems associated with dementia. "It tells us a little bit more about drug therapy and perhaps what might be affecting women and men differently," said Dr. Paula Rochon, a senior scientist at Toronto's Women College Hospital. In Wednesday's issue of the Journal of the American Geriatric Society, Rochon and her co-authors said of 21,526 older adults with dementia in Ontario who started taking the medications, about seven per cent of the women and nearly 11 per cent of the men died or were hospitalized during the 30 days after the treatment started. Little is known about how drugs may affect men and women differently after the age of 85, says Dr. Paula Rochon. "While younger women may be more likely than younger men to experience an adverse drug event, our results suggest that the incidence of serious events in the elderly is reversed and that older men are more likely than older women to experience a serious event related to atypical antipsychotic initiation," the study's authors concluded. © CBC 2013

Keyword: Alzheimers; Aggression
Link ID: 17667 - Posted: 01.10.2013

By BENEDICT CAREY Most adolescents who plan or attempt suicide have already received at least some mental health treatment, raising questions about the effectiveness of current approaches to helping troubled youths, according to the largest in-depth analysis to date of suicidal behaviors in American teenagers. Matt Nock, a professor of psychology at Harvard and the lead author of a study on the mental health treatment of troubled young people, said his research showed that “we’ve got a long way to go to do this right.” The study found that 55 percent of adolescents who plan or attempt suicide have already received some therapy. The study, in the journal JAMA Psychiatry, found that 55 percent of suicidal teenagers had received some therapy before they thought about suicide, planned it or tried to kill themselves, contradicting the widely held belief that suicide is due in part to a lack of access to treatment. The findings, based on interviews with a nationwide sample of more than 6,000 teenagers and at least one parent of each, linked suicidal behavior to complex combinations of mood disorders like depression and behavior problems like attention-deficit and eating disorders, as well as alcohol and drug abuse. The study found that about one in eight teenagers had persistent suicidal thoughts at some point, and that about a third of those who had suicidal thoughts had made an attempt, usually within a year of having the idea. © 2013 The New York Times Company

Keyword: Depression; Aggression
Link ID: 17665 - Posted: 01.10.2013

By DAVID DOBBS Psychological trauma dims tens of millions of lives around the world and helps create costs of at least $42 billion a year in the United States alone. But what is trauma, exactly? Both culturally and medically, we have long seen it as arising from a single, identifiable disruption. You witness a shattering event, or fall victim to it — and as the poet Walter de la Mare put it, “the human brain works slowly: first the blow, hours afterward the bruise.” The world returns more or less to normal, but you do not. In 1980, the Diagnostic and Statistical Manual of Mental Disorders defined trauma as “a recognizable stressor that would evoke significant symptoms of distress in almost everyone” — universally toxic, like a poison. But it turns out that most trauma victims — even survivors of combat, torture or concentration camps — rebound to live full, normal lives. That has given rise to a more nuanced view of trauma — less a poison than an infectious agent, a challenge that most people overcome but that may defeat those weakened by past traumas, genetics or other factors. Now, a significant body of work suggests that even this view is too narrow — that the environment just after the event, particularly other people’s responses, may be just as crucial as the event itself. The idea was demonstrated vividly in two presentations this fall at the Interdisciplinary Conference on Culture, Mind and Brain at the University of California, Los Angeles. Each described reframing a classic model of traumatic experience — one in lab rats, the other in child soldiers. © 2012 The New York Times Company

Keyword: Stress; Aggression
Link ID: 17637 - Posted: 12.27.2012

By RON LIEBER Insurance covers more mental health care than many people may realize, and more people will soon have the kind of health insurance that does so. But coverage goes only so far when there aren’t enough practitioners who accept it — or there aren’t any nearby, or they aren’t taking any new patients. In the days after the Newtown, Conn., school shooting, parents and politicians took to the airwaves to make broad-based proclamations about the sorry state of mental health care in America. But a closer look reveals a more nuanced view, with a great deal of recent legislative progress as well as plenty of infuriating coverage gaps. The stakes in any census of mental health insurance coverage are high given how many people are suffering. Twenty-six percent of adults experience a diagnosable mental disorder in any given year, and 6 percent of all adults experience a seriously debilitating mental illness, according to the National Institute of Mental Health. Twenty-one percent of teenagers experience a severe emotional disturbance between the ages of 13 and 18. According to this year’s Society for Human Resource Management survey of 550 employers of all sizes, including nonprofits and government entities, 85 percent offer at least some mental health insurance coverage. A 2009 Mercer survey found that 84 percent of employers with more than 500 employees covered both in-network and out-of-network mental health and substance abuse treatments. © 2012 The New York Times Company

Keyword: Depression
Link ID: 17628 - Posted: 12.22.2012

Continued high use of marijuana by the nation's eighth, 10th and 12th graders combined with a drop in perceptions of its potential harms in this year's Monitoring the Future survey, an annual survey of eighth, 10th, and 12th-graders conducted by researchers at the University of Michigan. The survey was carried out in classrooms around the country earlier this year, under a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The 2012 survey shows that 6.5 percent of high school seniors smoke marijuana daily, up from 5.1 percent five years ago. Nearly 23 percent say they smoked it in the month prior to the survey, and just over 36 percent say they smoked within the previous year. For 10th graders, 3.5 percent said they use marijuana daily, with 17 percent reporting past month use and 28 percent reporting use in the past year. The use escalates after eighth grade, when only 1.1 percent reported daily use, and 6.5 percent reported past month use. More than 11 percent of eighth graders said they used marijuana in the past year. The Monitoring the Future survey also showed that teens' perception of marijuana’s harmfulness is down, which can signal future increases in use. Only 41.7 percent of eighth graders see occasional use of marijuana as harmful; 66.9 percent see regular use as harmful. Both rates are at the lowest since the survey began tracking risk perception for this age group in 1991. As teens get older, their perception of risk diminishes. Only 20.6 percent of 12th graders see occasional use as harmful (the lowest since 1983), and 44.1 percent see regular use as harmful, the lowest since 1979.

Keyword: Depression; Aggression
Link ID: 17623 - Posted: 12.21.2012

By Yevgeniy Grigoryev and Spoonful of Medicine The recent tragedy in Newtown, Connecticut, perpetrated by 20 year-old Adam Lanza, has intensified the discussion about how mental health is handled and documented in the US. Officials have not provided information about Lanza’s motivation and state of mind, and many are rightfully quick to point out that it is wrong to equate mental illness with the fatal sociopathic actions of a small group of individuals. The conversation about access to mental health care should, however, take into account new data showing an increasing contribution of mental and behavioral disorders to deterioration in the health-related quality of life among teenagers in the US and Canada over the last two decades, and increases elsewhere around the globe. The estimation of ‘years lived with disabilities’, or YLDs, is used as a collective metric to determine how much a particular disorder deprives the population of healthy years of life during a particular window of time. In 2010 just as in 1990, depression ranked as the number two contributor of YLDs, affecting 4% of the global population, eclipsed only by back pain that affected almost 10% of population worldwide. Among 10 to 14 year olds, the top contributor worldwide is iron deficiency. Asthma had been the largest contributor to YLDs for youths in that age range in the US and Canada in 1990, but the study published in The Lancet on Thursday led by researchers at the Institute of Health Metrics and Evaluation (IHME) at the University of Washington, Seattle showed that in this group depression surpassed asthma to claim the number one spot in 2010. In that group, the collective number of ‘years lost to disability’ grew from about 140,000 in 1990 to almost 180,000 in 2010, a 30% increase. Notably, global figures for the same age group show that the number of years lost to disability from depression grew from 4.9 million in 1990 to 5.5 million in 2010, a 13% increase as shown in the graphs below. © 2012 Scientific American

Keyword: Depression; Aggression
Link ID: 17622 - Posted: 12.21.2012